Kite: A trial testing KITE-363 and KITE-753 in people with relapsed and refractory B-cell lymphoma
A phase 1 trial looking at the treatments KITE-363 and KITE-753 in adults with relapsed or refractory B-cell lymphoma.
You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT04989803
Trial aim and background
The aim of this trial is to find out about the safety and appropriate dose of the medications KITE-363 and KITE-753 in patients with relapsed or refractory B-cell lymphoma. These are both CAR-T therapies. Eligible study participants who have received either of the treatments will move on to a separate long-term follow up study for 15 years.
This is a phase 1 (early phase) trial. Little is known about the safety and effectiveness of this treatment. You might not benefit from the treatment, but the trial will give important information about this new treatment, which could help other people in the future.
Who can enter
Adults with B-cell lymphoma and at least one measurable lesion which has relapsed or become refractory to treatment, and who have adequate organ and bone marrow function may be eligible for this trial.
Locations
Recruitment is taking place at King’s College Hospital, London
Further information
More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT04989803
Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.